Apollomics (APLM) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing oncology therapies for difficult-to-treat and treatment-resistant cancers, with a pipeline of three active clinical-stage product candidates.

• Lead candidate vebreltinib is a selective c-Met inhibitor targeting NSCLC and other tumors with c-Met alterations, with orphan drug designation and regulatory approval in China for NSCLC with Met Exon 14 skipping.

• Operations are conducted through subsidiaries in the U.S., China, Australia, and Hong Kong, with a Cayman Islands holding company structure and no use of VIEs.

• Utilizes a biomarker-driven diagnostic approach and pursues both monotherapies and combination therapies to improve cancer treatment outcomes.

Financial performance and metrics

• As of December 31, 2025: $6.7 million in total assets, $6.3 million in total liabilities, and an accumulated deficit of $711.8 million.

• Net equity (deficit) reported at $(3.2) million.

• Significant cash transfers made to subsidiaries for working capital and investments, with $187.1 million to U.S. operations, $13.1 million to Australia, $18.6 million to Hong Kong, and $35 million to PRC subsidiaries.

Use of proceeds and capital allocation

• No proceeds from the offering will be received by the company; all shares sold are by selling securityholders.

• Company will bear registration costs, while selling securityholders bear incremental selling expenses.